Chronic Obstructive Pulmonary Disease (COPD), being a major cause of morbidity and mortality worldwide, is
a major problem for public health. It is predicted that its burden will continuously expand over the next years. This article
is an up-to-date review of both non-pharmacologic and pharmacologic management of COPD, which is now based on
new staging systems, able to predict prognosis and the response to different treatment approaches. Non-pharmacologic
therapies, such as smoking cessation, vaccinations and pulmonary rehabilitation are covered briefly. Current
pharmacologic management covers short acting beta-agonists (SABA), short acting muscarinic antagonists (SAMA), long
acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS
combinations, xanthines, specific phosphodiesterase 4 (PDE4) inhibitors and oxygen therapy.
Chronic obstructive pulmonary disease (COPD), disease management, pharmacotherapy, phenotypes,
State University of Medicine and Pharmacy “Nicolae Testemitanu”, Stefan cel Mare street 165, 2004 Chisinau, Republic of Moldova.